


AS ([mNew York Criteria](#)) Axial SpA ([ASAS Criteria](#))
Severe disease not adequately responding to NSAIDs:
Normally failure to respond or intolerance to
2 x NSAID at therapeutic dose
AND
BASDAI and VAS > 4



*Biosimilar versions of adalimumab, etanercept and infliximab available.

Select treatment based on presence of comorbidity

Choose therapy based on cost and presence of comorbidity

- If psoriasis present: recommend use of a MAB or secukinumab
- If inflammatory bowel disease or uveitis present: recommend MAB
- Use secukinumab with caution in inflammatory bowel disease

- Adequate response is defined as ≥ 2 points or 50% improvement from baseline assess BASDAI and ≥ 2 cm improvement Spinal Pain
- If inadequate response at 3 or 6 month assessment, reassess after 6 weeks of treatment.
- *Assess response at 16 weeks after starting secukinumab and 16 to 20 weeks after ixekizumab

1. For **Primary inefficacy** (total of 2 anti-TNF therapies, and secukinumab or ixekizumab)
2. For **Secondary inefficacy** - another approved high-cost drug may be used. Where secondary failure of efficacy may be a class effect, use another drug from an alternative drug class. Avoid using more than two anti-TNF agents unless involvement of anti-drug antibodies is the cause of failure.
3. **Adverse effect** - another approved high-cost drug may be used. Where adverse effect may be a class effect use another drug from an alternative drug class.